MESOBLAST LIMITED (MSB)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
MSB - MESOBLAST LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -1.71
Index: ASX300 | ALL-ORDS
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -1.71
Mesoblast is a Melbourne-headquartered medical research company investigating stem cell treatments and allogenic cellular medicines. The company was founded and listed in 2004.
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$1.065
14 May |
0.020 OPEN $1.04 |
1.91% HIGH $1.07 |
3,797,380 LOW $1.04 |
TARGET | |||||
|
|||||
Franking for last dividend paid out: 0% |
OTHER COMPANIES IN THE SAME SECTOR | |||
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO . |
FNARENA'S MARKET CONSENSUS FORECASTS
Title | FY24 Forecast |
FY25 Forecast |
---|---|---|
EPS (cps) | - 9.5 | xxx |
DPS (cps) | 0.0 | xxx |
EPS Growth | N/A | xxx |
DPS Growth | N/A | xxx |
PE Ratio | N/A | xxx |
Dividend Yield | 0.0% | xxx |
Div Pay Ratio(%) | N/A | xxx |
All estimates have been converted into AUD by FNArena at present FX values.
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -15.6 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 11.2 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 87.9 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -103.0 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -1,091.71 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -16.49 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -13.68 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -11.61 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -16.49 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -11.98 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -103.4 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 15 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 160 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 175 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | 202 M |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 107 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 1.22 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 0.5 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 4.19 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 41 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 78 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | 40 M |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 3 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
MSB STOCK CHART
FNArena News on MSB
1 |
April In Review: The Bond Market RoaredMay 06 2024 - Australia |
2 |
The Short Report – 21 Dec 2023Dec 21 2023 - Weekly Reports |
3 |
Dr Boreham’s Crucible: Paradigm BiopharmaceuticalsNov 06 2023 - Small Caps |
4 |
Weekly Ratings, Targets, Forecast Changes – 22-09-23Sep 25 2023 - Weekly Reports |
5 |
Dr Boreham’s Crucible: PainchekSep 11 2023 - Small Caps |
Latest Pharmaceuticals & Biotech/Lifesciences News
1 |
Dr Boreham’s Crucible: InvionMay 13 2024 - Small Caps |
2 |
Dr Boreham’s Crucible: Race OncologyApr 09 2024 - Small Caps |
3 |
The Power Of New Weight-Loss DrugsApr 03 2024 - International |
4 |
Dr Boreham’s Crucible: Neuren PharmaceuticalsMar 11 2024 - Small Caps |
5 |
Spotlight On ASX-Listed Cannabis CompaniesJan 31 2024 - Small Caps |
6 |
Transformational Trial Results For Neuren PharmaceuticalsDec 20 2023 - Small Caps |
7 |
Dr Boreham’s Crucible: ImugeneDec 11 2023 - Small Caps |
8 |
Dr Boreham’s Crucible: PYC TherapeuticsNov 22 2023 - Small Caps |
9 |
Dr Boreham’s Crucible: Paradigm BiopharmaceuticalsNov 06 2023 - Small Caps |
10 |
Dr Boreham’s Crucible: Argenica TherapeuticsSep 28 2023 - Small Caps |